How many insider trades does FilingIQ track for IBRX?

FilingIQ tracks 123 Form 4 insider transactions for IBRX (ImmunityBio, Inc.), covering filings from Mar 11, 2021 onwards. 3 of those are dated within the last 90 days.

Are IBRX insiders net buyers or net sellers?

Across the full Form 4 history for IBRX, 9 transactions (7%) were open-market purchases and 23 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IBRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is IBRX in?

ImmunityBio, Inc. (IBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.89B.

IBRX insider trading

Healthcare

ImmunityBio, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

123

Last 90 days

Buys / sells

7% / 19%

Market cap

$5.89B

About ImmunityBio, Inc.

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Company website: immunitybio.com

IBRX insider activity at a glance

FilingIQ tracks 123 insider transactions for IBRX in filings since Mar 11, 2021. The most recent transaction is dated Oct 5, 2026.

Across the full history, 9 open-market purchases and 23 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IBRX insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IBRX trades on FilingIQ Raw filings on SEC EDGAR

Latest IBRX Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 837

UNITED THERAPEUTICS Corp

BLLN 139

BillionToOne, Inc.

TMO 130

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

ONC 122

BeOne Medicines Ltd.

CORT 110

CORCEPT THERAPEUTICS INC

CSTL 104

CASTLE BIOSCIENCES INC

Frequently asked

How many insider trades does FilingIQ track for IBRX?: FilingIQ tracks 123 Form 4 insider transactions for IBRX (ImmunityBio, Inc.), covering filings from Mar 11, 2021 onwards. 3 of those are dated within the last 90 days.
Are IBRX insiders net buyers or net sellers?: Across the full Form 4 history for IBRX, 9 transactions (7%) were open-market purchases and 23 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IBRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is IBRX in?: ImmunityBio, Inc. (IBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.89B.

Methodology & sources

Every IBRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.